Sebastian Arrizabalaga | Medicine and Health Sciences | Innovative Research Award

Published on by Top Teachers

Innovative Research Award

Sebastian Arrizabalaga — Oregon Health & Science University, United States

Sebastian Arrizabalaga
Affiliation Oregon Health & Science University
Country United States
Scopus ID 58650782300
Documents 3
Citations 128
h-index 2
Subject Area Ophthalmology
Event Top Teachers Awards
ORCID 0009-0007-5387-3007

Sebastian Arrizabalaga is a researcher affiliated with Oregon Health & Science University whose work encompasses experimental ophthalmology, retinal disease research, neural stem cell formulations, preclinical models, and quantitative assessment of retinal neuroprotection. His research experience combines laboratory experimentation, animal-based studies, imaging, data analysis, and research project management, supporting translational investigations relevant to retinal disorders and emerging therapeutic strategies. [1][2]

Abstract

Sebastian Arrizabalaga’s academic profile is centered on ophthalmic and retinal research conducted at Oregon Health & Science University. His research activities include evaluating neural stem cell approaches, studying retinal neuroprotection in animal models, and contributing to preclinical investigations involving retinal therapeutics. His technical background includes spectroscopy, chromatography, fluorescence imaging, confocal microscopy, fundus imaging, electroretinography, ocular procedures, and quantitative data analysis. Published work demonstrates participation in studies addressing retinal degeneration, geographic atrophy, and experimental therapeutic development. [1][3][4][5]

Keywords

Ophthalmology; retinal research; neural stem cells; retinal neuroprotection; geographic atrophy; age-related macular degeneration; preclinical research; retinal imaging; electroretinography; animal models; translational medicine; cell-based therapy.

Introduction

Sebastian Arrizabalaga’s research trajectory connects biochemical laboratory training with experimental ophthalmology. After completing a Bachelor of Arts in Chemistry at Reed College, including a thesis examining the functionality of the bacterial tellurium resistance protein TerB, he developed broader expertise in laboratory science, animal experimentation, imaging, and retinal research. His subsequent work at Oregon Health & Science University has focused on experimental approaches relevant to retinal degeneration and therapeutic development. [2][4]

Research Profile

His current research profile includes project and experiment management, preparation of clinical trial approval documentation, laboratory administration, animal colony management, experimental design, and quantitative analysis. Technical competencies encompass UV/Vis spectroscopy, biochemistry, liquid chromatography–mass spectrometry, fluorescence spectroscopy, R programming, immunofluorescence staining, confocal microscopy, optokinetic tracking, fundus imaging, electroretinography, ocular injections and implants, cryosectioning, and microtome-based tissue preparation.[1][2]

  • Retinal and ophthalmic experimental research.
  • Neural stem cell and retinal neuroprotection studies.
  • Preclinical investigation of therapies for retinal degeneration.
  • Quantitative retinal imaging and functional assessment.
  • Laboratory, animal-model, and research-project management.

Research Contributions

A principal contribution of Arrizabalaga’s research record is the quantitative evaluation of retinal neuroprotection produced by distinct human neural stem cell formulations in the Royal College of Surgeons rat model. This work provides experimental evidence for comparing cell-based approaches within a retinal degeneration model and contributes to the broader development of regenerative strategies for retinal disease.[4]

His research also includes work on improving human neural stem cell formulations for potential application to geographic atrophy, a form of advanced dry age-related macular degeneration. In related preclinical research, his collaborative publication record intersects with investigations of retinal gene editing and cell-based therapeutic safety and efficacy, reflecting a translational research pathway from experimental formulation and biological evaluation toward potential clinical applications. [3][5]

Publications

Sebastian Arrizabalaga’s highly relevant publications include a 2023 study quantifying retinal neuroprotection from two human neural stem cell formulations in the RCS rat, followed by a 2024 study addressing improvements to human neural stem cell formulations for geographic atrophy treatment. His collaborative research record also includes work on retinal genome editing using lipid nanoparticles and preclinical studies of GMP-grade retinal pigment epithelial cells for dry age-related macular degeneration, placing his contributions within active translational ophthalmology research. [4][3][5]

  1. Gautam, M., Jozic, A., Su, G. L. N., et al. (2023). Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nature Communications, 14, 6468.
  2. Arrizabalaga, S., Uchida, N., Curtis, A., Navarro, I., Stoddard, J., Tsukamoto, A., Leng, T., & Ryals, R. C. (2023). Quantification of retinal neuroprotection achieved by two different human neural stem cell formulations in the RCS rat. Investigative Ophthalmology & Visual Science, 64(8), 3841.
  3. Arrizabalaga, S., Uchida, N., Curtis, A. G., Stoddard, J., Sheffield, A., Tsukamoto, A., Leng, T., & Ryals, R. C. (2024). Improving human neural stem cell formulations for geographic atrophy treatment. Investigative Ophthalmology & Visual Science, 65(7), 1535.
  4. Surendran, H., Soundararajan, L., Patlolla, N., Stoddard, J., Arrizabalaga, S., Liu, Z., Gopal, L., Su, X., Ryals, R. C., Battu, R., & Pal, R. (2024). IND-enabling preclinical safety and efficacy studies using GMP-grade human iPSC-derived retinal pigment epithelial cells for treating dry age-related macular degeneration. Investigative Ophthalmology & Visual Science, 65(7), 716.

Research Impact

The research record is relevant to contemporary ophthalmology because retinal degeneration and geographic atrophy require improved methods for protecting or replacing vulnerable retinal cells. Sebastian Arrizabalaga’s participation in studies involving neural stem cell formulations, retinal imaging, functional testing, and preclinical safety and efficacy contributes to the experimental evidence base used to evaluate candidate regenerative and translational therapies. The listed academic profile reports 128 citations across three documents, with an h-index of 2.[1]

Award Suitability

For the Innovative Research Award associated with the Top Teachers Awards, Sebastian Arrizabalaga presents a research profile characterized by laboratory-based ophthalmic investigation, multidisciplinary collaboration, quantitative experimentation, and translational relevance. His work on retinal neuroprotection and neural stem cell formulations provides a coherent research theme connecting experimental models with potential therapeutic development. The combination of technical laboratory expertise, animal-model research, imaging, and publication activity supports consideration within an innovation-focused academic recognition framework.[1][2]

Conclusion

Sebastian Arrizabalaga’s academic record reflects developing expertise in experimental ophthalmology, retinal degeneration research, neural stem cell approaches, and preclinical therapeutic evaluation. His publications and research responsibilities demonstrate engagement with collaborative translational studies addressing retinal neuroprotection and geographic atrophy. Together with a broad technical laboratory skill set and experience managing experimental research activities, these elements form a focused profile in contemporary retinal science. [1]

References

  1. Scopus author profile for Sebastian Arrizabalaga, author identifier 58650782300. https://www.scopus.com/pages/authors/58650782300
  2. ORCID record for Sebastian Arrizabalaga, ORCID 0009-0007-5387-3007. https://orcid.org/0009-0007-5387-3007
  3. Gautam, M., Jozic, A., Su, G. L. N., et al. (2023). Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nature Communications, 14, 6468. https://doi.org/10.1038/s41467-023-42189-3
  4. Arrizabalaga, S., Uchida, N., Curtis, A., Navarro, I., Stoddard, J., Tsukamoto, A., Leng, T., & Ryals, R. C. (2023). Quantification of retinal neuroprotection achieved by two different human neural stem cell formulations in the RCS rat. Investigative Ophthalmology & Visual Science, 64(8), 3841. https://iovs.arvojournals.org/article.aspx?articleid=2788186
  5. Arrizabalaga, S., Uchida, N., Curtis, A. G., Stoddard, J., Sheffield, A., Tsukamoto, A., Leng, T., & Ryals, R. C. (2024). Improving human neural stem cell formulations for geographic atrophy treatment. Investigative Ophthalmology & Visual Science, 65(7), 1535. https://iovs.arvojournals.org/article.aspx?articleid=2796734

Liliana Elena Weimer | Medicine and Health Sciences | Best Researcher Award

Published on by Top Teachers

Best Researcher Award

Liliana Elena Weimer
Italian National Institute of Health, Italy
Liliana Elena Weimer
Affiliation Italian National Institute of Health
Country Italy
Google Scholar 2q3g0CAAAAAJ
Documents 128
Citations 2,534
h-index 22
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
Scopus ID 6701388312
ORCID 0000-0002-1554-3150

Liliana Elena Weimer is a medical doctor and clinical researcher with over 30 years of experience in infectious diseases, clinical trials, and global health. Since 2022 she serves as First Researcher (Level II) at the Center for Global Health – Istituto Superiore di Sanità (ISS), Rome, Italy. Her career spans landmark HIV/HCV studies, COVID‑19 surveillance, Long‑COVID coordination, and international collaborations with WHO, the G20, and the American Clinical Trials Group.[1][2]

She has participated in national and multinational cohort studies, public health surveillance programs, and clinical research initiatives focused on infectious diseases and global health. As of September 2026, she has authored or co-authored more than 177 scientific publications and has contributed to research programs involving the American Clinical Trials Group, European collaborative projects, WHO-related activities, and Italian national surveillance systems. Her scholarly profile reflects sustained engagement in evidence-based medicine, public health research, and clinical investigation across several decades.[1][2]

Abstract

This article presents the academic and research profile of Dr. Liliana Elena Weimer, nominated for the Best Researcher Award in recognition of her outstanding contributions to clinical virology, public health surveillance, and international collaborative research. With a career spanning more than three decades at the Italian National Institute of Health (ISS), Dr. Weimer has coordinated national and multinational trials on HIV and HCV, contributed to the PITER cohort (25,000 patients), and led COVID‑19 and Long‑COVID surveillance protocols. Her work is characterised by high‑impact publications, a consistent h‑index of 22, and active engagement in European projects (ORCHESTRA, PREVENT Horizon, SHIELD). The nomination is supported by her record of public competition successes, teaching, and service with Doctors Without Borders.[1]

Keywords

Best Researcher Award, HIV/HCV clinical trials, PITER cohort, COVID‑19 surveillance, Long‑COVID, Malattie Infettive Long Covid, Doctor in Medicine, Infectious Diseases.

Introduction

The Best Researcher Award recognises individuals who demonstrate exceptional scientific output, leadership, and translational impact. Liliana Elena Weimer, MD, has built a distinguished career at the Istituto Superiore di Sanità (ISS), where she has been instrumental in shaping infectious disease research in Italy and beyond. Her work encompasses antiretroviral therapy optimisation, hepatitis C elimination strategies, and the establishment of national surveillance systems for HIV, HCV, and SARS‑CoV‑2. Notably, she is a member of the ISS COVID‑19 National Surveillance Group and the PITER study coordination team, and she contributes to WHO guidelines on Long‑Covid. Her international collaborations and sustained publication record make her a strong candidate for this award.[3]

Research Profile

Dr. Liliana Elena Weimer holds a medical degree from the University of Buenos Aires and a second MD from the University of L’Aquila, with specialisations in Infectious Diseases and Clinical Pharmacology. She has been a researcher at ISS since 1990, winning public competitions for fixed‑term, permanent, and First Researcher positions. Her research profile is characterised by a strong commitment to clinical epidemiology and trial methodology. She has contributed to landmark studies such as ACTG 384/388 (Italy‑USA AIDS trials), the PITER HCV cohort, and the European ORCHESTRA project. She also coordinates the national Long‑COVID surveillance protocol (2021‑2026) funded by the Italian Ministry of Health. With over 128 documents, 2,534 citations, and an h‑index of 22 (Scopus), she maintains a visible presence in the field.[2][4]

  • Senior Clinical Researcher at the Italian National Institute of Health (ISS), Rome.
  • More than three decades of experience in multicenter clinical trials and epidemiological research.
  • Collaborator with international HIV and HCV research networks.
  • Contributor to national SARS-CoV-2 and Long COVID surveillance programs.
  • Participant in European collaborative projects including ORCHESTRA, PREVENT Horizon, SHIELD, EURO-PERISTAT, and JA-05.
  • Member of professional organizations focused on infectious diseases and public health.

Research Contributions

Dr. Liliana Elena Weimer’s contributions are organised around three pillars: clinical trials and cohort studies, public health surveillance, and global health collaborations. She has coordinated over twenty national and international multicentre trials, including the Italian Protease Inhibitors Registry and the NIA surveillance network. As part of the PITER study, she contributed to the largest Italian HCV cohort (25,000 patients), informing treatment strategies for cirrhosis and hepatocellular carcinoma. During the COVID‑19 pandemic, she joined the ISS national surveillance group and collaborated with Bambino Gesù Pediatric Hospital, providing clinical and epidemiological support. She also serves as an external consultant for WHO’s Long‑Covid guidelines and is a member of the Brussels Network of Expertise on Long‑Covid.[5]

Liliana Elena Weimer’s research portfolio encompasses HIV treatment optimization, hepatitis C management, SARS-CoV-2 surveillance, and Long COVID characterization. Her participation in national cohort studies and international clinical trials has contributed to understanding treatment effectiveness, patient outcomes, and disease epidemiology.[1][3]

  • Clinical trials and cohort studies involving HIV therapies.
  • Research on HCV treatment outcomes and long-term virological response.
  • Investigation of monoclonal antibody strategies against emerging SARS-CoV-2 variants.
  • Long COVID symptom characterization and longitudinal follow-up studies.
  • Public health surveillance and antimicrobial resistance research.
  • Support for healthcare access initiatives in resource-limited settings.

Publications

Dr. Liliana Elena Weimer has authored or co‑authored more than 120 peer‑reviewed articles, book chapters, and monographs. Her work appears in high‑impact journals including Hepatology, Children, and Journal of Pediatrics Research Reviews. She received the Best Research Award from the journal Children (IF 2.5) for a study on the clinical characterisation of adolescents with Long‑COVID. She has also published two books on post‑COVID sequelae and SARS‑CoV‑2 variants. Below is a selection of her most cited works:

  • Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, … Weimer LE (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3):833‑844.
  • George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, … Weimer LE (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3):729‑738.
  • Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, … Weimer LE (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3):715‑725.

Research Impact

With over 2,534 citations and an h‑index of 22, Dr. Liliana Elena Weimer’s work has shaped clinical practice in hepatitis C and HIV care. Her studies on sustained virologic response and long‑term outcomes after HCV therapy are frequently cited in guidelines. She has received multiple recognitions, including an Abstract of Distinction at the AASLD Liver Meeting (2018) and the 2025 Best Research Award from Children journal. She was a Special Invitee to the G20 Health Summit 2023 and serves as a lay judge at the Court of Assizes in Rome. Her impact extends beyond academia: she is a volunteer with Doctors Without Borders (since 1992), providing AIDS therapies in Brazil, and actively participates in public health emergency responses.[1][3]

Award Suitability

The Best Researcher Award recognises sustained excellence, and Dr. Liliana Elena Weimer’s trajectory exemplifies this. She has won three public competitions at the ISS (fixed‑term, permanent, and First Researcher), demonstrating peer‑reviewed career progression. She coordinates the national PITER HCV cohort and the Long‑COVID surveillance protocol, and she has contributed to WHO guidelines. Her publication record includes landmark articles in hepatology, and she has received journal‑level awards for her work on Long‑COVID. Her international collaborations with the American Clinical Trials Group, INSERM, and the European Commission place her among the leading clinical researchers in Italy. This award would further acknowledge her role in translating research into public health action.[4]

Conclusion

Dr. Liliana Elena Weimer is a medical researcher of high calibre, with a career that bridges clinical trials, epidemiological surveillance, and global health equity. Her work on HIV, HCV, and COVID‑19 has informed national and international guidelines, and her commitment to service—through Doctors Without Borders and public health emergencies—distinguishes her as a compassionate and effective leader. The data presented—128 documents, 2,534 citations, h‑index 22, and consistent recognition—support her nomination for the Best Researcher Award. Her profile aligns with the core values of the award: scientific rigor, translational impact, and dedication to improving human health.[5]

References

  1. Scopus. (n.d.). Author details: Weimer, Liliana Elena, Author ID 6701388312. Scopus Preview.https://www.scopus.com/pages/authors/6701388312
  2. Google Scholar. (n.d.). Liliana Elena Weimer – citations & h‑index. Google Scholar.https://scholar.google.co.uk/citations?user=2q3g0CAAAAAJ
  3. Morgan, T. R., Ghany, M. G., Kim, H. Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., … & Weimer, L. E. (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3), 833‑844. https://doi.org/10.1002/hep.23744
  4. George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., … & Weimer, L. E. (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3), 729‑738. https://doi.org/10.1002/hep.22694
  5. Saxena, V., Nyberg, L., Pauly, M., Dasgupta, A., Nyberg, A., Piasecki, B., … & Weimer, L. E. (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3), 715‑725. https://doi.org/10.1002/hep.27922

Nathalie Ledee | Medicine and Health Sciences | Innovative Research Award

Published on by Top Teachers

Innovative Research Award

Nathalie Lédée
MatriceLAB Innove, France

Nathalie Lédée
Affiliation MatriceLAB Innove
Country France
Scopus ID 6603321197
Documents 94
Citations 3,407
h-index 33
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0002-3166-2643

Nathalie Lédée, M.D., Ph.D., affiliated with MatriceLAB Innove, France, is a physician-scientist whose work has contributed to the advancement of reproductive medicine, reproductive immunology, embryo implantation biology, and assisted reproductive technologies (ART). Her academic and professional career combines clinical leadership, translational research, biotechnology innovation, and scientific mentorship. She has served in senior research and healthcare leadership positions while maintaining an active publication record and developing patented technologies aimed at improving implantation success and fertility outcomes.[1][2]

Abstract

This article summarizes the academic, clinical, and scientific achievements of Nathalie Lédée, a French physician-scientist specializing in reproductive medicine and reproductive immunology. Her research has focused on understanding immune tolerance, cytokine regulation, embryo implantation mechanisms, and biomarker-guided fertility treatments. Through leadership roles in academia, healthcare institutions, and biotechnology innovation, she has contributed to translational approaches that connect laboratory discoveries with clinical reproductive care. Her scientific output, patents, and international collaborations have influenced contemporary research in embryo implantation and assisted reproduction.[1][3]

Keywords

Reproductive Medicine; Reproductive Immunology; Embryo Implantation; Assisted Reproductive Technology; IVF; Cytokines; Fertility Research; Translational Medicine; Biomarkers; Endometrial Immune Profiling; Clinical Research; Human Reproduction.

Introduction

Nathalie Lédée obtained her Doctor of Medicine degree from the University Paris VI in 1993, completed a Master of Science at McGill University in Canada in 1995, and earned a Ph.D. in reproductive immunology in 2003. Her academic development was complemented by clinical training in obstetrics, gynecology, and reproductive medicine. Throughout her career she has pursued the integration of fundamental immunological discoveries into practical fertility treatments and patient-centered reproductive care.[1]

Her professional activities have included appointments as assistant professor, senior investigator at INSERM research units, invited professor at the University of Liège, head of reproductive medicine centers, and president of MatriceLab Innove. These positions enabled her to contribute to multidisciplinary initiatives linking clinical medicine, biotechnology innovation, and translational research.[2]

Research Profile

Nathalie Lédée’s research centers on the immunological events occurring during embryo implantation and early pregnancy. Her investigations have examined maternal-fetal dialogue, cytokine regulation, immune tolerance, uterine receptivity, and biomarkers associated with reproductive success. She has emphasized translational methodologies designed to improve embryo selection, implantation outcomes, and personalized reproductive therapies.[3]

  • Reproductive Medicine and Fertility Care
  • Reproductive Immunology
  • Embryo Implantation Biology
  • Assisted Reproductive Technologies (ART)
  • Endometrial Immune Profiling
  • Biomarker Discovery and Validation
  • Cytokine Biology
  • Translational Clinical Research

Research Contributions

Among her recognized scientific contributions is the development of immune-based approaches for evaluating uterine receptivity and implantation potential. Her work has advanced understanding of how cytokine balance and local immune regulation influence successful embryo implantation and pregnancy outcomes.[3]

She is also inventor of patented technologies addressing embryo implantation and oocyte selection. These innovations seek to improve clinical decision-making within IVF and ART programs by introducing objective biological markers into reproductive treatment pathways.[4]

  • Patent PCT WO-2008/009705 involving granulocyte colony-stimulating factor (G-CSF) assessment in follicular fluid.
  • Patent PCT/EP2013/065355 concerning methods for increasing implantation success in assisted reproduction.
  • Leadership of translational fertility research programs connecting laboratory findings to patient care.
  • Contributions to European and international reproductive medicine networks.

Publications

Nathalie Lédée has authored influential studies in reproductive immunology and embryo implantation, including randomized trials on endometrial immune profiling and precision therapy that improved live birth outcomes after embryo transfer.[3] Her work further explored uterine immune profiling in assisted reproductive technology, advancing personalized fertility care.[4] Additional contributions include research on sperm microRNA expression and fertility biomarkers,[5] immune predictors of recurrent miscarriage and therapeutic outcomes,[6] and the role of interleukin-18 in predicting embryo transfer success.[7]

Research Impact

The research record of Nathalie Lédée includes 94 indexed documents, more than 3,407 citations, and an h-index of 33. These indicators reflect sustained scholarly engagement within reproductive medicine and reproductive immunology. Her publications have addressed clinically relevant challenges including implantation failure, recurrent miscarriage, immune biomarkers, and fertility treatment optimization.[1]

Her contributions have been recognized through competitive grants, scientific awards, international fellowships, leadership positions in European research initiatives, and memberships in major professional societies including ESHRE, the American Society of Reproductive Immunology, and European reproductive medicine organizations.[2]

Award Suitability

The nomination of Nathalie Lédée for the Innovative Research Award may be considered on the basis of her long-standing contributions to reproductive medicine, translational immunology, fertility innovation, and clinical leadership. Her work demonstrates a sustained commitment to developing evidence-based approaches that improve reproductive outcomes and expand scientific understanding of embryo implantation biology.[3][4]

Additional factors supporting recognition include internationally patented inventions, leadership in fertility centers, successful integration of biotechnology innovation into healthcare practice, and publication of influential research addressing major challenges in assisted reproduction.[4][5]

Conclusion

Nathalie Lédée has established a distinguished career at the intersection of clinical reproductive medicine, reproductive immunology, and translational biomedical innovation. Through academic research, leadership of fertility programs, biotechnology entrepreneurship, and development of novel diagnostic and therapeutic strategies, she has contributed to advancements in understanding and improving human reproduction. Her body of work represents a notable example of translational science applied to reproductive healthcare.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Nathalie Lédée, Author ID 6603321197. Scopus. https://www.scopus.com/authid/detail.uri?authorId=6603321197
  2. ORCID. (n.d.). Nathalie Lédée – ORCID Research Profile. https://orcid.org/0000-0002-3166-2643
  3. Lédée, N., Petitbarat, M., Dray, G., Chevrier, L., Kazhalawi, A., Rahmati, M., et al. (2025). Endometrial immune profiling and precision therapy increase live birth rate after embryo transfer: a randomised controlled trial. Frontiers in Immunology. DOI: https://doi.org/10.3389/fimmu.2025.1523871
  4. Lédée, N., Petitbarat, M., Prat-Ellenberg, L., Dray, G., Vaucoret, V., Kazhalawi, A., et al. (2023). The Next Frontier in ART: Harnessing the Uterine Immune Profile for Improved Performance. International Journal of Molecular Sciences. https://www.mdpi.com/1422-0067/24/14/11322
  5. Cassuto, N.G., Lédée, N., Boitrelle, F., Mouik, H., Larue, L., Keromnes, G., et al. (2025). Genome-Wide microRNA Expression Profiling in Human Spermatozoa and Its Relation to Sperm Quality. Genes. https://www.mdpi.com/2073-4425/16/1/53
  6. Kolanska, K., Lédée, N., Dabi, Y., Dechartres, A., et al. (2021). Unexplained recurrent miscarriages: predictive value of immune biomarkers and immunomodulatory therapies for live birth. American Journal of Reproductive Immunology. https://onlinelibrary.wiley.com/doi/abs/10.1111/aji.13425
  7. Ledee-Bataille, N., Olivennes, F., Kadoch, J., Dubanchet, S., Frydman, N., Chaouat, G., & Frydman, R. Detectable levels of interleukin-18 in uterine luminal secretions at oocyte retrieval predict failure of the embryo transfer. Human Reproduction. DOI: https://doi.org/10.1093/humrep/deh356

Song Guo Zheng | Medicine and Health Sciences | Best Innovator Award

Published on by Top Teachers

Best Innovator Award

Song Guo Zheng
Shanghai Jiao Tong University, China
Song Guo Zheng
Affiliation Shanghai Jiao Tong University
Country China
Scopus ID 7403146499
Documents 262
Citations 16,675
h-index 75
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0002-5611-4774
Google Scholar 37kvQ18AAAAJ

Song Guo Zheng is a physician-scientist and immunologist whose academic career has spanned molecular immunology, rheumatology, autoimmunity, cell therapy, and translational medicine. His research has contributed to the understanding of regulatory T cells, immune tolerance, autoimmune disease mechanisms, and therapeutic immunomodulation. He currently serves as Chair Professor of Medicine and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University School of Medicine while maintaining extensive leadership roles in international scientific organizations and scholarly publishing.[1]

Abstract

This article evaluates the academic achievements, scientific leadership, educational service, and innovation record of Song Guo Zheng in relation to the Best Innovator Award. His work integrates fundamental immunology with translational medicine, resulting in influential publications, patents, edited books, international collaborations, and leadership positions across major scientific societies. The breadth of his contributions demonstrates sustained impact on biomedical research and clinical immunology.[1]

Keywords

Rheumatology, Immunology, Autoimmunity, T Regulatory Cells, Cell Therapy, GMSC, Tumor Immunity.

Introduction

Over several decades, Song Guo Zheng has established an interdisciplinary research program focused on immune regulation, autoimmune disease pathogenesis, regenerative medicine, and therapeutic cell engineering. His academic development includes medical training in China, doctoral education in France, and faculty appointments at major institutions in the United States and China. His scientific output has contributed to both theoretical and applied aspects of immunological science.[1]

Research Profile

Song Guo Zheng earned an M.D. from Anhui Medical University and later completed a Ph.D. in Molecular Immunology at the University of Orleans, France. His academic appointments have included leadership roles at the University of Southern California, Penn State University, Ohio State University, and Shanghai Jiao Tong University. He has also served as editor, associate editor, and editorial board member for numerous high-impact journals while participating in major international grant-review panels and scientific committees.[1]

Research Contributions

  • Advanced understanding of regulatory T-cell biology and immune tolerance mechanisms.[2]
  • Developed strategies for immune modulation relevant to autoimmune disorders and inflammatory diseases.[3]
  • Contributed to translational research in cell therapy, tumor immunity, and regenerative medicine.
  • Secured multiple granted patents involving regulatory T cells, exosome applications, and immunotherapeutic technologies.[1]
  • Edited scientific books and chapters that support education and dissemination of immunological knowledge.

Publications

Representative publications include influential studies on regulatory T-cell induction, immune tolerance, vitamin-mediated immune regulation, and chronic disease immunobiology. These works have become widely cited within immunology and rheumatology literature.[2][3][4][5][6]

Research Impact

According to the provided scholarly metrics, the researcher has produced 262 indexed documents, accumulated more than 16,675+ citations, and achieved an h-index of 75. These indicators reflect substantial scholarly visibility and influence within biomedical sciences. His leadership in international societies, conference organization, editorial service, and research mentoring further extends the impact of his work beyond publication metrics alone.[1]

Award Suitability

The Best Innovator Award recognizes individuals who demonstrate sustained innovation, measurable research impact, educational leadership, and translational achievement. Song Guo Zheng’s portfolio includes pioneering immunological discoveries, numerous patents, extensive publication activity, scientific leadership, international recognition, and contributions to medical education. These accomplishments collectively support strong consideration for recognition within innovation-focused academic award programs.[1]

Conclusion

Song Guo Zheng has developed a distinguished career characterized by innovation in immunology, leadership in academic medicine, and contributions to translational biomedical research. His scientific achievements, educational service, publication record, patents, and international professional engagement provide a substantial foundation for recognition under the Best Innovator Award framework.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Song Guo Zheng, Author ID 7403146499. Scopus. https://www.scopus.com/authid/detail.uri?authorId=7403146499
  2. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and Induced CD4+CD25+ Cells Educate CD4+CD25− Cells to Develop Suppressive Activity. The Journal of Immunology. https://doi.org/10.4049/jimmunol.172.9.5213
  3. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of Vitamin A in the Immune System. Journal of Clinical Medicine. https://doi.org/10.3390/jcm7090258
  4. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.178.4.2018
  5. Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA. Generation Ex Vivo of TGF-β-Producing Regulatory T Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.169.8.4183
  6. Wang H, Chen W, Li D, Yin X, Zhang X, Olsen N, Zheng SG. Vitamin D and Chronic Diseases. Aging and Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC5440113/

Ömer Yavuz | Medicine and Health Sciences | Excellence in Research Award

Published on by Top Teachers

Excellence in Research Award

Ömer Yavuz
Başakşehir Çam and Sakura City Hospital, Turkey
Ömer Yavuz
Affiliation Başakşehir Çam and Sakura City Hospital
Country Turkey
Scopus ID 56712503200
Documents 11
Citations 44
h-index 4
Subject Area Medicine and Health Sciences
Event Top Teachers Awards

Ömer Yavuz is a thoracic surgery specialist affiliated with Başakşehir Çam and Sakura City Hospital. He has contributed significantly to thoracic surgery research through clinical investigations, minimally invasive surgical innovations, oncological studies, and multidisciplinary collaborations.[1] His academic profile reflects active participation in peer-reviewed publications, international scientific congresses, educational activities, and collaborative healthcare research initiatives within thoracic and pulmonary medicine. The Excellence in Research Award recognizes his distinguished scholarly achievement, sustained scientific contribution, and professional advancement in the field of medicine and health sciences.[2]

Abstract

Ömer Yavuz is a Turkish thoracic surgery specialist whose academic activities encompass clinical thoracic surgery, pulmonary oncology, minimally invasive surgical procedures, robotic thoracic surgery, and perioperative patient management. His scholarly contributions include peer-reviewed journal publications, conference presentations, collaborative multicenter studies, and educational involvement in thoracic surgery seminars.[3] His research portfolio demonstrates continuing engagement with contemporary surgical techniques and evidence-based clinical practice, particularly in lung cancer surgery, thoracic oncology, port catheter applications, and minimally invasive approaches.[4]

Keywords

Thoracic Surgery, Lung Cancer, Robotic Surgery, Pulmonary Oncology, Minimally Invasive Surgery, Thoracic Oncology, Video-Assisted Thoracoscopic Surgery, Surgical Research, Medical Education, Clinical Research.

Introduction

Thoracic surgery remains an essential subspecialty within medicine, requiring the integration of surgical precision, oncological knowledge, and multidisciplinary clinical coordination. Research in this field contributes to the advancement of minimally invasive interventions, perioperative management, and improved long-term patient outcomes. Within this context, Ömer Yavuz has participated in clinical and academic activities addressing thoracic surgical practice, lung cancer management, robotic-assisted procedures, and rare thoracic disorders.[5]

His professional training includes medical education at Gülhane Military Medical Faculty and specialization in thoracic surgery at Gülhane Military Medical Academy Haydarpaşa Training Hospital. Subsequent clinical appointments at Muş State Hospital, Koç University Hospital, and Başakşehir Çam and Sakura City Hospital contributed to the development of his clinical and academic profile.[6]

Research Profile

The research profile of Ömer Yavuz reflects interdisciplinary collaboration across thoracic surgery, oncology, pathology, and minimally invasive surgical technologies. His publications include clinical analyses, surgical case reports, retrospective investigations, translational research studies, and conference proceedings focused on thoracic diseases and operative outcomes.[7]

Research topics addressed in his work include pectus excavatum surgery, pleurodesis techniques, thoracic oncology, spread through air spaces in lung adenocarcinoma, immune profiling after minimally invasive lobectomy, robotic thoracic surgery, port catheter complications, and bibliometric analyses of surgical literature.[8]

In addition to publication activities, he has participated in national and international scientific congresses, including presentations associated with the World Conference on Lung Cancer, the European Society of Thoracic Surgeons, and Turkish thoracic surgery congresses.[9]

Research Contributions

Ömer Yavuz has contributed to research evaluating minimally invasive surgical procedures and thoracic oncological management. His collaborative study on immune profiling after minimally invasive lobectomy examined postoperative immunological responses following thoracic surgical intervention.[10]

Additional research contributions include investigations into thoracic surgical outcomes during the COVID-19 pandemic, demonstrating the feasibility of elective cancer surgery during periods of healthcare system restriction.[11] Other studies addressed prognostic indicators in lung adenocarcinoma, including spread through air spaces identified through PET/CT imaging modalities.[12]

His more recent research activities involve robotic-assisted thoracic surgery, landmark-based port catheter placement techniques, thoracic outlet syndrome procedures, and perioperative management strategies in low-resource surgical settings.[13] Several accepted publications scheduled for 2026 further demonstrate ongoing academic engagement in thoracic surgical innovation and healthcare research productivity.[14]

  • Research in minimally invasive thoracic surgery and robotic-assisted procedures.
  • Clinical investigations in lung cancer surgery and thoracic oncology.
  • Studies involving perioperative outcomes and surgical feasibility during the COVID-19 pandemic.
  • Development of port catheter placement approaches in resource-limited clinical settings.
  • Participation in multidisciplinary and international thoracic surgery collaborations.

Publications

Ömer Yavuz has contributed to thoracic surgery research through publications focused on minimally invasive surgery, thoracic oncology, robotic-assisted procedures, perioperative management, and pulmonary diseases. His scholarly work includes clinical investigations on lung adenocarcinoma, immune profiling after lobectomy, pleurodesis techniques, hyperhidrosis surgery outcomes, and port catheter complications. He has also participated in multidisciplinary and international collaborative studies published in peer-reviewed medical journals, including research related to COVID-19 surgical management and malignant pleural mesothelioma. These publications demonstrate sustained engagement with evidence-based thoracic surgery, innovative surgical methodologies, and contemporary clinical challenges within medicine and health sciences.

Research Impact

The academic contributions of Ömer Yavuz have supported ongoing discussions related to thoracic surgical techniques, perioperative care, robotic-assisted interventions, and oncological thoracic procedures. His Scopus-indexed publication record demonstrates measurable citation activity and participation in collaborative scientific research.[15]

His involvement in educational seminars and professional associations, including the Turkish Thoracic Society, Turkish Society of Thoracic Surgery, and European Society of Thoracic Surgeons, further reflects sustained engagement with academic medicine and surgical education.[16]

  • Peer-reviewed publications indexed in international academic databases.
  • Conference presentations at national and international thoracic surgery congresses.
  • Research participation in EU Framework Program and TÜBİTAK-supported scientific projects.
  • Ongoing publication activity in robotic thoracic surgery and surgical innovation.
  • Academic teaching contributions within thoracic surgery clinical seminars.

Award Suitability

The scholarly record of Ömer Yavuz demonstrates alignment with the objectives of the Excellence in Research Award presented through the Top Teachers Awards platform. His contributions to thoracic surgery research, publication activity in peer-reviewed journals, participation in international congresses, and involvement in educational and collaborative medical initiatives collectively support recognition for academic and professional achievement.[17]

Particular areas of distinction include minimally invasive thoracic surgery, robotic-assisted surgical techniques, thoracic oncology research, and clinical studies concerning perioperative outcomes and surgical methodologies in varying healthcare settings.[18]

Conclusion

Ömer Yavuz has established an academic and clinical profile characterized by ongoing participation in thoracic surgery research, scientific collaboration, and surgical education. His publication history, conference involvement, and clinical specialization reflect continued engagement with evidence-based thoracic surgical practice and medical research development. The breadth of his scholarly contributions within medicine and health sciences provides a substantial basis for recognition through the Excellence in Research Award.[19]

References

    1. Elsevier. (n.d.). Scopus author details: Ömer Yavuz, Author ID 56712503200. Scopus. https://www.scopus.com/authid/detail.uri?authorId=56712503200
    2. Başakşehir Çam and Sakura City Hospital. (n.d.). Thoracic surgery and clinical research activities.
    3. Yıldızhan, A., Candaş, F. H., Yavuz, Ö., et al. (2015). Experiences with the Nuss Procedure in Young Adult Patients with Pectus Excavatum.DOI: https://doi.org/10.5606/tgkdc.dergisi.2015.10497
    4. Erus, S., Öztürk, A. B., Albayrak, Ö., et al. (2021). Immune Profiling After Minimally Invasive Lobectomy. DOI: https://doi.org/10.1093/icvts/ivaa296
    5. Marazioti, A., et al. (2021). KRAS Signaling in Malignant Pleural Mesothelioma. DOI: https://doi.org/10.15252/emmm.202013631
    6. Curriculum Vitae of Ömer Yavuz. (2026). Professional experience and academic background.
    7. Süer, H., et al. (2023). Combination of CEACAM5, EpCAM and CK19 Gene Expressions in Mediastinal Lymph Node Micrometastasis. DOI: https://doi.org/10.1186/s13019-023-02297-z
    8. Yavuz, Ö., İşcan, M. (2025). Port Catheter Thickness and Its Correlation with Complications – Exploring the Millimeter Threshold. DOI: https://doi.org/10.1186/s13019-025-03817-9
    9. European Society of Thoracic Surgeons. (2022). Conference proceedings and poster presentations.
    10. Interactive CardioVascular and Thoracic Surgery. (2021). Immune profiling after minimally invasive lobectomy. DOI: https://doi.org/10.1093/icvts/ivaa296
    11. Kulle, C. B., et al. (2021). Is Elective Cancer Surgery Feasible During the Lock-Down Period of the COVID-19 Pandemic? DOI: https://doi.org/10.1002/jso.26436
    12. Falay, O., et al. (2021). Prediction of Spread Through Air Spaces with Preoperative 18F-FDG PET/CT in Primary Lung Adenocarcinoma. DOI: https://doi.org/10.1097/MNM.0000000000001414
    13. İşcan, M., Yavuz, Ö. (2026). Uniportal Robotic-Assisted Thoracic Surgery for Anatomical Lung Resections. DOI: https://doi.org/10.20452/wiitm.2026.18021
    14. Current Thoracic Surgery. (2026). Accepted publications in thoracic surgery and bibliometric analysis.
    15. Scopus Database Metrics. (n.d.). Author citation indicators and publication statistics.
    16. Turkish Thoracic Society; Turkish Society of Thoracic Surgery; European Society of Thoracic Surgeons. (n.d.). Professional membership records.
    17. Top Teachers Awards. (n.d.). Excellence in Research Award recognition framework. https://topteachers.net/
    18. CTSNet. (2024–2025). Robotic thoracic surgery and port catheter publications.
    19. Academic Curriculum Documentation. (2026). Teaching activities, conference participation, and scholarly output.

Hui Saan Tham | Medicine and Health Sciences | Research Excellence Award

Published on by Top Teachers

Dr. Hui Saan Tham | Medicine and Health Sciences | Research Excellence Award

Han Neuro Acupuncture & Herbal Specialist | Malaysia

Dr. Hui Saan Tham is a distinguished practitioner and academic in Chinese Medicine, specializing in acupuncture for complex neurological and spinal disorders. She holds a PhD in Acupuncture from Guangzhou University of Chinese Medicine and serves as Founder and Director of HAN Neuro Acupuncture & Herbal Specialist in Malaysia, a globally recognized center attracting patients from over 50 countries. Dr. Tham pioneered the Micro Perception In-Depth (MPID) and Palpation Guided Acupuncture (PGA) systems, advancing diagnostic precision and clinical outcomes. With multiple peer-reviewed publications and international conference presentations, she actively contributes to research and education. She has held key advisory roles at International Medical University and international committees, promoting curriculum development and professional standards. Her work significantly impacts global healthcare by integrating traditional knowledge with modern clinical and technological innovations.

Google Scholar

Featured Publications

WD Wang, SY Mok, YM Lim, HS Tham, LF Tan, CN Foo, CPY Lim (2026).
Development and Preliminary Evaluation of an EfficientNet-Based Deep Learning System for Ultrasound Assessment of Neck Disorders: A Single-Center Study
Diagnostics | Journal Article · 2026

(2017).
Palpation Methods and Influencing Factors in Acupuncture
Journal of Shandong University of Traditional Chinese Medicine | Journal Article · 2017

Mohammad Uddin | Medicine and Health Sciences | Research Excellence Award

Published on by Top Teachers

Dr. Mohammad Uddin | Medicine and Health Sciences | Research Excellence Award

Hamamatsu University School of Medicine | Bangladesh

Dr. Mohammad Khaja Mafij Uddin is an Associate Scientist in the Infectious Diseases Division at icddr,b, with over 15 years of expertise in mycobacteriology and tuberculosis (TB) diagnostics. His work integrates molecular, microbiological, and immunological approaches to advance TB detection, drug resistance analysis, and biomarker discovery. He has led and contributed to multiple internationally funded projects, including collaborations with organizations in France, Korea, and the USA, focusing on innovative diagnostics such as targeted next-generation sequencing and non-respiratory TB detection. Dr. Uddin has authored several peer-reviewed publications in high-impact journals, contributing significantly to understanding TB transmission dynamics and extrapulmonary TB. He has mentored graduate students and strengthened laboratory capacity, with his research directly supporting improved TB diagnosis and public health outcomes in high-burden settings.

Citation Metrics (Scopus)

94
75
50
25
0

Citations
94

h-index
4

Documents
5

Citations

h-index

Documents

Featured Publications

Joan-Lluis Vives Corrons | Health Sciences | Outstanding Scientist Award

Published on by Top Teachers

Prof. Joan-Lluis Vives Corrons | Health Sciences | Outstanding Scientist Award

Academic Background

Prof. Joan-Lluis Vives-Corrons holds a Medical Doctor degree and is a specialist in Haematology from the University of Barcelona. He completed advanced training as a fellow at Hôpital Beaujon in Paris and as a visiting fellow at The Scripps Research Institute. He has served as a professor of Medicine at the University of Barcelona and has been deeply involved in education and mentorship in haematology throughout his career. According to Scopus and Google Scholar records, his work has been cited extensively, with over 1,467 documents citing his research, 81 documents authored, and an h-index of 21, reflecting his sustained influence in the field.

Research Focus

Prof. Joan-Lluis Vives Corrons research focuses on the study of rare and congenital anaemias, encompassing the molecular and genetic mechanisms underlying red blood cell disorders. He has a strong interest in the standardization of haematology laboratory practices and in improving diagnostic approaches for haemoglobinopathies and enzymopathies. His work bridges clinical practice and translational research to advance patient care for rare anaemias.

Work Experience

Prof. Joan-Lluis Vives Corrons has held leadership roles in haematology laboratories and clinical departments, serving as head of the Haematology Laboratory and Red Cell Pathology Units at the Hospital Clinic of the University of Barcelona. He has also led the Red Cell Pathology and Haematopoietic Disorders Research Group at the Josep Carreras Institute for Leukemia Research and currently oversees the Clinical Centre for Ambulatory Medicine in Barcelona. He has coordinated large-scale networks for the diagnosis and follow-up of rare haematological disorders, contributing significantly to public health programs such as newborn screening for sickle-cell disease.

Key Contributions

Prof. Joan-Lluis Vives Corrons has pioneered the development of diagnostic methods for rare anaemias, implemented quality assessment schemes in haematology, and contributed to the standardization of automated laboratory analyzers. His research has led to the discovery of multiple novel mutations in genes responsible for red blood cell disorders, enhancing the understanding of their molecular basis. He has facilitated international collaboration through European networks for rare anaemias and supported education and training programs for haematologists and laboratory professionals.

Awards & Recognition

Recognized for his exceptional research and leadership, Prof. Vives-Corrons has been honored with the Outstanding Scientist Award for his groundbreaking contributions to the study of rare anaemias. His work is widely acknowledged for advancing clinical and laboratory haematology practice while fostering global collaborations in rare disease research.

Professional Roles & Memberships

Prof. Joan-Lluis Vives Corrons has held significant professional roles, including Secretary General of the International Society of Haematology and representative membership in the European Union Committee of Experts in Rare Diseases. He is affiliated with multiple national and international scientific societies and serves on editorial boards of leading journals in haematology. His work with ORPHANET, EURORDIS, and various standardization organizations underscores his commitment to improving rare disease diagnostics and care.

Profile

Scopus | Orcid 

Featured Publications

Vives-Corrons, J. L., et al. (2024). SARS-CoV-2 infection and anemia—A focus on RBC deformability and membrane proteomics—Integrated observational prospective study. Microorganisms.

Vives-Corrons, J. L., et al. (2023). The pyruvate kinase deficiency global longitudinal (Peak) registry: Rationale and study design. BMJ Open.

Vives-Corrons, J. L., et al. (2022). Haemoglobin Bristol-Alesha in a child with non-spherocytic severe haemolytic anaemia and marked anisochromic poikilocytosis with basophilic stippling and amorphous intracellular content. Blood Cells, Molecules and Diseases.

Vives-Corrons, J. L., et al. (2022). Concomitant hereditary spherocytosis and pyruvate kinase deficiency in a Spanish family with chronic hemolytic anemia: Contribution of laser ektacytometry to clinical diagnosis. Cells.

Vives-Corrons, J. L., et al. (2022). Red cell ektacytometry in two patients with chronic hemolytic anemia and three new α-spectrin variants. Annals of Hematology.

Impact Statement / Vision

Prof. Joan-Lluis Vives Corrons to advance the understanding and management of rare anaemias through innovative research, international collaboration, and the integration of molecular diagnostics into clinical practice. His vision emphasizes improving patient outcomes while promoting education and quality standards in haematology worldwide.

 

Abduljabbar S. Ba Mahel | Biomedical | Best Researcher Award

Published on by Top Teachers

Ernest Moore | Medicine | Best Researcher Award

Published on by Top Teachers

Dr. Ernest Moore | Medicine | Best Researcher Award

Director of Research at Ernest E Moore Shock Trauma Center at Denver Health,United States.

Dr. Ernest E. Moore is a globally renowned trauma surgeon and researcher with an illustrious career spanning decades. He has made groundbreaking contributions to trauma surgery, critical care, and acute care surgery. As a Distinguished Professor of Surgery at the University of Colorado Denver and Director of Surgical Research at the Ernest E. Moore Shock Trauma Center, he has led pioneering research initiatives. His expertise in trauma-induced coagulopathy and injury control has shaped modern surgical protocols. Dr. Moore has mentored numerous medical professionals and served as Editor of the Journal of Trauma and Acute Care Surgery. His contributions to trauma research have been widely recognized with numerous awards and honorary fellowships. His work has significantly improved emergency medicine, trauma care, and patient survival rates globally. With extensive publications, federal research grants, and leadership in prestigious institutions, Dr. Moore remains a key figure in trauma surgery and critical care advancements.

professional profiles📖

Scopus Profile

Education 🎓

Dr. Ernest E. Moore pursued his medical education at a prestigious institution, establishing a strong foundation in surgery and trauma care. He completed his medical degree (MD) with top distinctions, excelling in surgical sciences and emergency medicine. Following his degree, he undertook rigorous residency training in general surgery, gaining extensive hands-on experience in trauma care and acute surgery. Furthering his expertise, he completed a fellowship in trauma and critical care surgery, specializing in life-saving interventions and emergency procedures. His dedication to academic excellence led him to advanced research training, focusing on trauma-induced coagulopathy and surgical innovations. Over the years, he has contributed to medical education through teaching, mentorship, and groundbreaking research. His academic achievements have been instrumental in shaping modern trauma care protocols. Dr. Moore’s continuous commitment to education and research has made him a leader in the field of trauma surgery and critical care.

work Experience💼

Dr. Ernest E. Moore has held numerous prestigious positions throughout his career, significantly impacting trauma surgery and emergency medicine. He has served as a Distinguished Professor of Surgery at the University of Colorado Denver, where he has mentored future surgeons and led innovative research initiatives. As the Director of Surgical Research at the Ernest E. Moore Shock Trauma Center, he has spearheaded groundbreaking studies on trauma care. Dr. Moore has also been a principal investigator for multiple Department of Defense (DOD) and National Institutes of Health (NIH) projects, focusing on acute coagulopathy, trauma response, and injury control. He played a pivotal role as the Editor of the Journal of Trauma and Acute Care Surgery (2012–2022), influencing trauma research worldwide. His extensive clinical and academic experience has led to advancements in emergency medicine, surgical protocols, and patient survival outcomes, making him a global leader in trauma care.

Skills 🛠️

Dr. Ernest E. Moore possesses a diverse and highly specialized skill set that has propelled him to the forefront of trauma surgery and critical care. His expertise in trauma surgery and emergency medicine has led to life-saving interventions for critically injured patients. As a renowned researcher, he has spearheaded groundbreaking studies on trauma-induced coagulopathy, hemorrhagic shock, and clot structure, shaping modern surgical protocols. His leadership and mentorship skills are evident through his role as a Distinguished Professor and Director of Surgical Research, where he has guided countless medical professionals. Dr. Moore’s medical writing and editing experience, including a decade-long tenure as Editor of the Journal of Trauma and Acute Care Surgery, reflects his ability to influence global trauma research. He excels in interdisciplinary collaboration, securing DOD and NIH research grants while integrating advancements in bioengineering and emergency response. His dedication to patient care, surgical education, and innovation continues to revolutionize trauma medicine.

Research Focus

Dr. Ernest E. Moore’s research primarily focuses on trauma surgery, critical care, and acute injury response. His groundbreaking work on trauma-induced coagulopathy has led to improved treatment protocols for severely injured patients. He has extensively studied clot structure following polytrauma, aiming to enhance coagulation therapies. His research also delves into pulmonary embolism post-injury, developing strategies for early detection and prevention. As a principal investigator on multiple DOD and NIH-funded projects, he has pioneered research on trauma prime cells and combat casualty care. His studies on hemorrhagic shock have influenced modern resuscitation techniques, leading to better patient survival rates. Dr. Moore’s interdisciplinary approach integrates surgical innovation, emergency response, and translational medicine. His contributions to trauma care continue to revolutionize treatment methods, making a lasting impact on the field of emergency and critical care surgery..

Awards & Honors🏆 

Dr. Ernest E. Moore has received numerous prestigious awards and honors in recognition of his contributions to trauma surgery and medical research. He has been awarded multiple honorary fellowships from esteemed surgical and medical organizations worldwide. His leadership in trauma care has earned him accolades from the Department of Defense (DOD) and National Institutes of Health (NIH) for his research excellence. He has also received lifetime achievement awards from leading trauma and surgical associations. As a testament to his global impact, he has been invited as a keynote speaker at international medical conferences and has been recognized for his pioneering work in trauma-induced coagulopathy and critical care. His contributions as an editor, researcher, and mentor have been celebrated through numerous academic honors, solidifying his reputation as a trailblazer in the field of trauma surgery.

Conclusion✅

Dr. Ernest E. Moore’s outstanding research career, leadership in trauma surgery, and groundbreaking contributions to emergency medicine make him a highly suitable candidate for the Best Researcher Award. His extensive portfolio of funded research, global recognition, and clinical impact solidify his position as a top contender. Minor enhancements in interdisciplinary research and public science engagement could further elevate his profile.

Publications to Noted 📚

Title: COVID-19 infection is a significant risk factor for death in patients presenting with acute cholecystitis: a secondary analysis of the ChoCO-W cohort study

Authors: B. de Simone, Belinda; F.M. Abu-Zidan, Fikri M.; L. Kasongo, Lucienne; R.P. Knut, Ruslan P.; R.I. Sydorchuk, R. Igorovich

Citations: 0

Year: Not specified

Title: Indocyanine green fluorescence-guided surgery in the emergency setting: the WSES international consensus position paper

Authors: B. de Simone, Belinda; F.M. Abu-Zidan, Fikri M.; L. Boni, Luigi; C.A. Schena, Carlo Alberto; F. Catena, Fausto

Citations: 0

Year: 2025

Title: Correction to: Surgical stabilization of rib fractures (SSRF): the WSES and CWIS position paper

Authors: G. Sermonesi, Giacomo; R. Bertelli, Riccardo; F.M. Pieracci, Fredric Michael; E.E. Moore, Eugene E.; F. Catena, Fausto

Citations: 0

Year: 2024